The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). At present, the COVID-19 has been prevalent worldwide for more than a year and caused more than four million deaths. Liver injury was frequently observed in patients with COVID-19. Recently, a new definition of metabolic dysfunction associated fatty liver disease (MAFLD) was proposed by a panel of international experts, and the relationship between MAFLD and COVID-19 has been actively investigated. Several previous studies indicated that the patients with MAFLD had a higher prevalence of COVID-19 and a tendency to develop severe type of respiratory infection, and others indicated that liver injury would be exacerbated in the patients with MAFLD once infected with COVID-19. The mechanism underlying the relationship between MAFLD and COVID-19 infection has not been thoroughly investigated, and recent studies indicated that multifactorial mechanisms, such as altered host angiotensin converting enzyme 2 (ACE2) receptor expression, direct viral attack, disruption of cholangiocyte function, systemic inflammatory reaction, drug-induced liver injury, hepatic ischemic and hypoxic injury, and MAFLD-related glucose and lipid metabolic disorders, might jointly contribute to both of the adverse hepatic and respiratory outcomes. In this review, we discussed the relationship between MAFLD and COVID-19 based on current available literature, and summarized the recommendations for clinical management of MAFLD patients during the pandemic of COVID-19. Highlights • MAFLD was associated with increased risk and severity of COVID-19. • 31% of COVID-19 patients had MAFLD. • COVID-19 promoted liver injury and progression of MAFLD, especially in the youth. • The mechanism of liver injury in patients with COVID-19 was multifactorial. •Early screen and active treatment of MAFLD is recommended for patients with COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, Liver injury, Fatty liver, MAFLD, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, ACE2, coronavirus, progression, angiotensin converting enzyme, respiratory infection, Viral, COVID-19 infection, severity of COVID-19, International, Patient, Youth, Liver injury, Clinical management, Fatty liver, mechanisms, receptor, respiratory, disease, expression, mechanism, Glucose, Drug-induced liver injury, angiotensin, Injury, deaths, COVID-19 patient, Disruption, fatty liver disease, active treatment, Metabolic disorders, acute respiratory syndrome, acute respiratory syndrome coronavirus, increased risk, enzyme, present, previous study, pandemic of COVID-19, tendency, respiratory outcomes, metabolic dysfunction, multifactorial, Host, recommendation, prevalent, hypoxic, systemic inflammatory, develop, caused, indicated, the patient, investigated, exacerbated, contribute, promoted, infected with COVID-19, patients with COVID-19, prevalence of COVID-19, 【제목키워드】 management, disease, dysfunction, metabolic,